India spinner Ravindra Jadeja was suspended on Sunday (6) for the third Test against Sri Lanka as his accumulated demerit points reached six within a 24-month period following his latest breach of the ICC Code of Conduct.
Jadeja threw the cricket ball at opener Dimuth Karunaratne off his own bowling when the batsman was inside the crease and the umpire ruled it "dangerous".
The latest breach added three demerit points to his tally, resulting in his suspension.
The third Test against Sri Lanka starts August 12 in Pallekel. Jadeja has also been slapped with a 50 per cent fine on his match fee (Level 2 offence).
Jadeja admitted to the offence and accepted the sanction proposed by ICC Match Referee Richie Richardson.
The charge was laid by on-field umpires Bruce Oxenford and Rod Tucker, third umpire Richard Illingworth and fourth umpire Ruchira Palliyaguruge.
In Jadeja's absence, left-arm chinaman Kuldeep Yadav is expected to play his second Test match at Pallekele (Kandy).
According to the ICC media release: "During the third day's play in the Colombo Test against Sri Lanka on Saturday (5), Jadeja was found guilty of breaching article 2.2.8 of the ICC Code of Conduct for Player and Player Support Personnel, which relates to "throwing a ball (or any other item of cricket equipment such as a water bottle) at or near a player, player support personnel, umpire, match referee or any other third person in an inappropriate and/or dangerous manner during an International Match."
Jadeja had received a 50 per cent fine and three demerit points during the Indore Test against New Zealand in October 2016 for violating 2.2.11 of the Code.
With the addition of these three demerit points, he has reached the threshold of four demerit points, which, pursuant to article 7.6 of the Code, have now been converted into two suspension points.
Two suspension points equate to a ban from one Test or two ODIs or two T20Is, whatever comes first for the player.
Following this suspension, the six demerit points will remain on Jadeja's disciplinary record. If Jadeja reaches the next threshold of eight or more demerit points within a 24-month period, then they will be converted into four suspension points.
Four suspension points equate to a ban from two Tests or four ODIs or four T20Is, whatever comes first for the player.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.